Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744460 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL5940026 | 0.96 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL5940033 | 0.96 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL25177834 | 0.91 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL31347351 | 0.91 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL25177835 | 0.91 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL25969763 | 0.88 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL19965342 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL16551786 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL7993092 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | SYNGENTA CROP PROTECTION AG (CH) | 2006-08-10 | — | — | US | disclosed |
| EP-1593681-A1 | TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
| WO-1994002477-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | HSD17B10 160/4885SMN1; SMN2 4012/4885NPC1 3/4885 |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | CCR4, CCR5, CCR1 | HSD17B10 2112/4885SMN1; SMN2 1369/4885NPC1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.